GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN - Top-Institutions - MDSpire

GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN

  • By

  • Yuri Gorelik

  • Itai Ghersin

  • Rona Lujan

  • Dima Shlon

  • Yiska Loewenberg Weisband

  • Amir Ben-Tov

  • Eran Matz

  • Galia Zacay

  • Iris Dotan

  • Dan Turner

  • Haggai Bar-Yoseph

  • October 23, 2024

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Endocrinology
    • Metabolic Disease

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Diabetes and Obesity
    • Immunology

  • #3

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Endocrinology
    • Translational Medicine

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Diabetes Research
    • Immunology

  • #5

    Harvard Medical School / Massachusetts General Hospital
    Harvard Medical School / Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Endocrinology
    • Clinical Research

Original Source(s)

GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN

  • by Yuri Gorelik, Itai Ghersin, Rona Lujan, Dima Shlon, Yiska Loewenberg Weisband, Amir Ben-Tov, Eran Matz, Galia Zacay, Iris Dotan, Dan Turner, Haggai Bar-Yoseph

  • October 23, 2024

Related Content

Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children

Correction: Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation